



CURRICULUM VITAE

Daniel K. Nomura, Ph.D.

Professor
University of California, Berkeley
Innovative Genomics Institute
2151 Berkeley Way, Rm 312G
Berkeley, CA 94720
DNomura@berkeley.edu
Office: 510-643-7258
Cell: 510-798-9647
Nomuraresearchgroup.com

Education

- 2008-2011 Postdoctoral Fellow in Chemical Physiology
Scripps Research (Advisor: Benjamin F. Cravatt)
- 2004-2008 Ph.D. in Molecular Toxicology
University of California, Berkeley (Advisor: John E. Casida)
- 1999-2003 B.A. in Molecular and Cell Biology
University of California, Berkeley (Advisor: John E. Casida)

Positions

- 2022-current Professor (with tenure)
University of California, Berkeley
Department of Chemistry
Department of Molecular and Cell Biology, Division of Molecular Therapeutics
- 2022-current Director, Novartis-Berkeley Translational Chemical Biology Institute (NB-TCBI)
- 2019-2022 Professor (with tenure)
University of California, Berkeley
Departments of Chemistry, Molecular and Cell Biology, and Nutritional Sciences and Toxicology
- 2019-current Adjunct Professor
University of California, San Francisco; Department of Pharmaceutical Chemistry
- 2017-2022 Director, Novartis-Berkeley Center for Proteomics and Chemistry Technologies (NB-CPACT)
- 2016-2019 Associate Adjunct Professor
University of California, San Francisco
Department of Pharmaceutical Chemistry
- 2015-2019 Associate Professor (with tenure)
University of California, Berkeley
Departments of Nutritional Sciences and Toxicology, Chemistry, and Molecular and Cell Biology
- 2011-2015 Assistant Professor
University of California, Berkeley
Department of Nutritional Sciences and Toxicology
- 2008-2011 Postdoctoral Fellow
The Scripps Research Institute, La Jolla, CA
Department of Chemical Physiology
Advisor: Professor Benjamin F. Cravatt
- 2004-2008 Graduate Researcher
- 2003-2004 Research Associate
- 2000-2003 Undergraduate Research Assistant
University of California, Berkeley
Department of Nutritional Sciences and Toxicology
Advisor: Professor John E. Casida

Daniel K. Nomura Biography

Dan Nomura is a Professor of Chemical Biology and Molecular Therapeutics in the Department of Chemistry and the Department of Molecular and Cell Biology in the Division of Molecular Therapeutics at the University of California, Berkeley and an Investigator at the Innovative Genomics Institute. He is also an Adjunct Professor in the Department of Pharmaceutical Chemistry at UCSF. Since 2017, he has also been the Director of the Novartis-Berkeley Translational Chemical Biology Institute focused on using chemoproteomic platforms to tackle the undruggable proteome. He is also Co-Founder of Frontier Medicines, a start-up company focused on using chemoproteomics and machine learning approaches to tackle the undruggable proteome. He is also the Founder of Vicinitas Therapeutics based on his group's discovery of the Deubiquitinase Targeting Chimera (DUBTAC) platform for targeted protein stabilization. He is also on the Scientific Advisory Boards for Frontier Medicines, Vicinitas Therapeutics, Photys Therapeutics, Apertor Pharma, and the Mark Foundation for Cancer Research and is on the Investment Advisory Board of Droia Ventures. He earned his B.A. in Molecular and Cell Biology and Ph.D. in Molecular Toxicology at UC Berkeley with Professor John Casida and was a postdoctoral fellow at Scripps Research with Professor Benjamin F. Cravatt before returning to Berkeley as a faculty member in 2011. Among his honors include the National Cancer Institute Outstanding Investigator Award, Searle Scholar, American Cancer Society Research Scholar Award, and the Mark Foundation for Cancer Research ASPIRE award.

Major Research Directions

1. Chemoproteomics-enabled covalent ligand discovery platforms to tackle the undruggable proteome
2. Expanding the scope of targeted protein degradation using chemoproteomic platforms
3. Discovering new induced proximity-based therapeutic modalities

The Nomura Research Group is focused on reimagining druggability using chemoproteomic platforms to develop transformative medicines. One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered "undruggable," in that most proteins do not possess known binding pockets or "ligandable hotspots" that small-molecules can bind to modulate protein function. Our research group addresses this challenge by advancing and applying chemoproteomic platforms to discover and pharmacologically target unique and novel ligandable hotspots for disease therapy. We currently have three major research directions. Our first major focus is on developing and applying chemoproteomics-enabled covalent ligand discovery approaches to rapidly discover small-molecule therapeutic leads that target unique and novel ligandable hotspots for undruggable protein targets and pathways. Our second research area focuses on using chemoproteomic platforms to expand the scope of targeted protein degradation technologies. Our third research area focuses on using chemoproteomics-enabled covalent ligand discovery platforms to develop new induced proximity-based therapeutic modalities. Collectively, our lab is focused on developing next-generation transformative medicines through pioneering innovative chemical technologies to overcome challenges in drug discovery.

Awards and Fellowships

2022	National Cancer Institute Outstanding Investigator Award
2019	Mark Foundation for Cancer Research ASPIRE award
2015	ACS Research Scholar Award
2015	DOD Breakthroughs Award Recipient
2014	Finalist in DOD Era of Hope Breast Cancer Research Award (top 5 candidates)
2013	Eicosanoid Research Foundation Young Investigator Award
2013	Selected US (ACS) Representative for Transatlantic Frontiers of Chemistry Conference
2013	Hellman Fellows Awardee
2013	Michael J. Fox Foundation Target Validation Award
2012	Ellison Foundation for Aging Research Award (declined)
2012	Searle Scholar Award

2012	Outstanding Research Achievement Award from Nature Biotechnology/Amgen at SF <i>SciCafe</i>
2010	NIH Pathway to Independence (PI) Award (K99/R00)
2009	American Cancer Society Postdoctoral Fellowship
2009	California Breast Cancer Research Program Postdoctoral Fellowship (declined)
2008	Adelle Davis Award for Nutritional Sciences Research

Affiliations

2022-current	Droia Ventures Investment Advisory Board member
2022-current	Faculty in the Department of Molecular and Cell Biology, Molecular Therapeutics Division (UC Berkeley)
2022-current	Director, Novartis-Berkeley Translational Chemical Biology Institute
2022-current	Scientific Advisory Board member of Ecto Therapeutics
2022-current	Scientific Advisory Board member of Apertor Pharmaceuticals
2022-current	American Association for Cancer Research (AACR) Chemistry in Cancer Research Working Group Steering Committee member
2022-current	Founder, Chair of the Scientific Advisory Board, and Member of the Board of Directors for Vicinitas Therapeutics
2022-current	Associate Editor, Chemical Research in Toxicology
2021-current	Scientific Advisory Board member of Photys Therapeutics
2021-2022	Consultant for Droia Ventures
2021-current	Scientific Advisory Board member of Zenagem Therapeutics
2021-current	Editorial Board Member of Cell Chemical Biology
2021-current	Scientific Advisory Committee Member, Mark Foundation for Cancer Research
2020-current	Scientific Advisory Board for the Undruggables, Kisaco Research
2019-current	Investigator, Innovative Genomics Institute
2018-2021	Associate Editor of Cell Chemical Biology
2018-current	Editor of Current Protocols in Chemical Biology
2018-current	Co-Founder, Chair of the Scientific Advisory Board, and Consultant for Frontier Medicines
2018-current	Editorial Advisory Board for Chemical Research in Toxicology
2017-2022	Director, Novartis-Berkeley Center for Proteomics and Chemistry Technologies
2016-current	Member, UCSF Helen Diller Family Comprehensive Cancer Center
2016-current	Member, UCSF Breast Oncology Program
2016-2022	Faculty in the Department of Molecular and Cell Biology, Biochemistry, Biophysics, and Structural Biology Division (UC Berkeley)
2016-current	Adjunct Professor at UCSF, Department of Pharmaceutical Chemistry
2015-current	Faculty in the Department of Chemistry (UC Berkeley)
2012-current	Member of the Synthetic Biology Institute (UC Berkeley)
2012-2019	Adviser for Abide Therapeutics
2012-current	Endocrinology Graduate Group (UC Berkeley)
2011-2022	Program in Metabolic Biology (UC Berkeley)
2011-current	Member of Chemical Biology Graduate Group (UC Berkeley)
2011-current	Member of Molecular Toxicology Graduate Group (UC Berkeley)
2011-2022	Member of Molecular and Biochemical Nutrition Graduate Group (UC Berkeley)
2011-2022	Faculty in the Department of Nutritional Sciences and Toxicology (UC Berkeley)

Professional Associations

2004-current	American Chemical Society
2021-current	American Association for Cancer Research member
2004-2008	Society of Toxicology

Academic Services

2022-current	Director, Novartis-Berkeley Translational Chemical Biology Institute
2021	Member, Faculty selection committee for hiring in chemistry for the Department of Chemistry
2020-current	Molecular and Cell Biology graduate admissions committee member

2018-2019	NST space committee
2018	Cal Day NST Speaker
2018-2020	Miller Fellow Advisory Committee for the Department of Chemistry
2017-2022	Director, Novartis-Berkeley Center for Proteomics and Chemistry Technologies
2017-2021	Member, Animal Care and Use Committee
2017-2019	Member, College of Natural Resources Executive Committee
2017	Cal Day NST Speaker
2016-2017	Member, Faculty selection committee for hiring in cancer biology for the Molecular and Cell Biology department
2016-2017	Member, Faculty selection committee for hiring the next chair for the Nutritional Sciences and Toxicology department
2016-2017	Faculty adviser for Chemistry-Chemical Biology students
2016-2022	Member, Executive/Long Range Planning committee for Nutritional Sciences and Toxicology
2016-2017	Member, working group to advise on academic realignment as it pertains to the College of Natural Resources and the L&S Biological Sciences Division
2016-2021	Member, Committee for Laboratory and Environmental Biosafety
2014-current	Chair and Head Graduate Adviser, Molecular Toxicology Graduate Program
2014-2018	Member, CNR Student Faculty Relations Committee
2014	Member, Molecular and Cell Biology Cancer Faculty Search Committee
2014	Speaker for CalSO Faculty Showcase
2013-2017	Member, Metabolic Biology Graduate Affairs Committee
2012-current	Regents' and Chancellors' Scholarship Faculty Mentor
2012	Member, Faculty Selection committee for the Nutritional Sciences and Toxicology Department
2012-2017	Member, Seminar Speaker Selection Committee
2011-2018	Member, Undergraduate Affairs Committee for the Nutritional Sciences and Toxicology Department
2011-current	Member, Molecular Toxicology Graduate Affairs Committee

Professional Services

2022-current	Standing Member for NIH Chemical Biology and Probes Study Section (CBP)
2022-current	Director, Novartis-Berkeley Translational Chemical Biology Institute
2022-2022	Standing Member for NIH Synthetic and Biological Chemistry A Study Section (SBCA)
2022-current	Associate Editor for Chemical Research in Toxicology
2022	Vice Chair for Bioorganic Chemistry Gordon Research Conference
2021-2022	External Scientific Consultant for the National Cancer Institute Fusion Oncoproteins in Childhood Cancers (FuSOnC2) Program
2021-current	Editorial Board Member of Cell Chemical Biology
2018-2021	Editor of Cell Chemical Biology
2018-current	Editor of Current Protocols in Chemical Biology
2018-current	Editorial Advisory Board for Chemical Research in Toxicology
2018	Discussion Leader at 2018 Bioorganic Chemistry Gordon Research Conference, Andover, New Hampshire.
2018	Study section ad hoc member for Enabling Bioanalytical and Imaging Technologies (EBIT) study section
2018	Chair and organizer of EMBO meeting "Enzymes, biocatalysis and chemical biology: The new frontiers" Pavia, Italy.
2018	Chair and organizer of "Chemoproteomics and Metabolomics" session at 2018 ASBMB Experimental Biology meeting, San Diego
2017-2019	Study section ad hoc member for Cancer Drug Development & Therapeutics (CDDT) study section
2017-2022	Director, Novartis-Berkeley Center for Proteomics and Chemistry Technologies

2016	Study section ad hoc member for Recurring Special Emphasis Panel NIH ZRG1 BMCT-C(01) Molecular Targets and Cancer Intervention study section
2016	Study section member for Special Emphasis Panel NIH ZRG1 BSTU 50
2015	Editor for "Omics" Issue in Current Opinions in Chemical Biology
2015-2018	Adviser for 3-V Biosciences
2012-2019	Adviser for Abide Therapeutics (Acquired by Lundbeck Pharma in 2019)
2011	Editor Special Issue for Biochimica Biophysica Acta (Lipids in Cancer)

Reviewer for: Cell, Molecular Cell, Cell Chemical Biology, Cell Metabolism, Cell Reports, Chemical Neurosciences, Chemical Reviews, Nature, Nature Chemical Biology, Nature Cell Biology, Chemical Sciences, PNAS, Biochimica et Biophysica Acta, Journal of the American Chemical Society, Nature Structural and Molecular Biology, Journal of Lipid Research, Journal of Clinical Investigation, Cancer and Metabolism, Molecular and Cellular Proteomics, ACS Chemical Biology, ACS Central Science, Journal of Biological Chemistry, eLife, Nature Chemistry

Teaching

Fall 2022	UC Berkeley Instructor for Advanced Toxicology (NST110)
Fall 2022	UC Berkeley Instructor for Chemical Biology (Chem135)
Spring 2022	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2021	UC Berkeley Instructor for Freshman Seminar on: Chemical Biology as an Engine for Drug Discovery (Chem 24)
Fall 2021	UC Berkeley Instructor for
Spring 2021	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2021	UC Berkeley Instructor for Research in Toxicology (NST193)
Fall 2020	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2020	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2020	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2020	UC Berkeley Instructor for Advanced Seminar in MCB (MCB290)
Fall 2019	UC Berkeley Instructor for Advanced Toxicology (NST110)
Fall 2018	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2018	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2018	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2017	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2017	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2017	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2016	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2016	UC Berkeley Instructor for Research in Toxicology (NST193)
Spring 2016	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2015	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2015	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2015	UC Berkeley Instructor for Research in Toxicology (NST193)
Fall 2014	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2014	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Fall 2013	UC Berkeley Instructor for Advanced Toxicology (NST110)
Spring 2013	UC Berkeley Instructor for Introduction to Toxicology (NST11)
Spring 2012	UC Berkeley Instructor for Graduate Research Colloquium (NST292)
Spring 2012	UC Berkeley Instructor for Graduate Seminar (NST290): Chemical Approaches to Study Metabolism
Fall 2011	UC Berkeley Instructor for Undergraduate Special Seminar (NST190): "-Omic Approaches to Study Metabolism"
Spring 2007	UC Berkeley Lecturer for Molecular Toxicology (NST120)
Fall 2006	UC Berkeley Co-Instructor and Graduate Student Instructor for Advanced Toxicology (NST110)
Spring 2006	UC Berkeley Guest Lecturer for Pesticide Chemistry and Toxicology (ESPM148)
Spring 2006	UC Berkeley Lecturer for Molecular Toxicology (NST120)

Publications

2022

1. Toriki ES*, Papatzimas JW*, Nishikawa K, Dovala D, McGregor LM, Hesse MJ, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2022) Rational chemical design of molecular glue degraders. *BioRxiv* doi: <https://doi.org/10.1101/2022.11.04.512693>. (* co-first authorship)
2. King EA, Cho Y, Dovala D, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2022) Chemoproteomics-Enabled Discovery of a Covalent Molecular Glue Degradator Targeting NF- κ B. *BioRxiv* <https://doi.org/10.1101/2022.05.18.492542>.
3. Henning NJ*, Boike L*, Spradlin JN, Ward CC, Liu G, Zhang E, Belcher BP, Brittain SM, Hesse M, Dovala D, McGregor LM, Veldez Misiolek R, Plasschaert LW, Rowlands DJ, Wang F, Frank AO, Fuller D, Estes AR, Randal KL, Panidapu A, McKenna JM, Tallarico JA, Schirle M, **Nomura DK** (2022) Deubiquitinase-targeting chimeras for targeted protein stabilization. *Nature Chemical Biology*, 18, 412-421. PMID 35210618 (* co-first authorship)
4. Henning NJ*, Manford AG*, Spradlin JN, Brittain SM, McKenna JM, Tallarico JA, Schirle M, Rape M[#], **Nomura DK**[#] (2022) Discovery of a covalent FEM1B recruiter for targeted protein degradation applications. *Journal of the American Chemical Society* 144, 701-708. PMID 34994556 (*co-first authorship; #co-corresponding authorship)
5. Shin HR, Citron YR, Wang L, Tribouillard L, Goul CS, Stipp R, Sugawara Y, Jain A, Samson N, Lim C-Y, Davis OB, Castaneda-Carpio D, Qian M, **Nomura DK**, Perera RM, Park E, Covey DF, Laplante M, Evers AS, Zoncu R (2022) Lysosomal GPCR-like protein LYCHOS signals cholesterol sufficiency to mTORC1. *Science* 10.1126/science.abg6621.
6. Boike L, Henning NJ, **Nomura DK** (2022) Advances in covalent drug discovery. *Nature Reviews Drug Discovery*, <https://doi.org/10.1038/s41573-022-00542-z>.
7. Maza JC, Garcia-Almedina DM, Boike LE, Hamlisch NX, **Nomura DK**, Francis MB (2022) Tyrosinase-Mediated Synthesis of Nanobody-Cell Conjugates. *ACS Central Science* <https://doi.org/10.1021/acscentrsci.1c01265>.
8. Benjamin DI, Both P, Benjamin JS, Nutter CW, Tan JH, Kang J, Machado LA, Klein JDD, de Morree A, Kim S, Liu L, Dulay H, Feraboli L, Louie SM, **Nomura DK**, Rando TA (2022) Fasting induces a highly resilient deep quiescent state in muscle stem cells via ketone body signaling. *Cell Metabolism* 34, 1-17.
9. Moon P*, Boike L*, Dovala D*, Henning NJ*, Knapp M*, Spradlin JN*, Ward CC*, Wolleb H*, Zammit CM*, Fuller D, Blake G, Murphy JP, Wang F, Lu Y, Moquin SA, Tandeske L, Hesse MJ, McKenna JM, Tallarico JA, Schirle M, Toste FD[#], **Nomura DK**[#] (2022) Discovery of potent pyrazoline-based covalent SARS-CoV-2 main protease inhibitors. *BioRxiv*, Submitted. (*co-first authors; #co-corresponding authors)
10. Page ACS, Scholz SO, Keenan KN, Spradlin JN, Belcher BP, Brittain SM, Tallarico JA, McKenna JM, Schirle M, **Nomura DK***, Toste FD* (2022) Photo-Brook rearrangement of acyl silanes as a strategy for photoaffinity probe design. *Chemical Science* 13, 3851-3856. PMID 35432890 (*co-corresponding author)

2021

11. Belcher BP, Ward CC, **Nomura DK** (2021) Ligandability of E3 ligases for targeted protein degradation applications. *Biochemistry* doi:10.1021/acs.biochem.1c00464. PMID 34473924
12. Trauner D, Fischer C, Nynke V, Peitsinis Z, Ruhmann P, Yang C, Spradlin J, Dovala D, **Nomura D**, Zhang Y (2021) De novo design of SARS-CoV-2 Main Protease Inhibitors. *Synlett*, 33, 458-463. PMID 35282568
13. **Nomura DK**, Dey M (2021) Advances and opportunities in targeted protein degradation. *Cell Chemical Biology* 15, 887-888. PMID 34270936
14. Spradlin JN, Zhang E, **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. *Accounts of Chemical Research*. 54, 1801-1813. PMID 33733731
15. Luo M*, Spradlin JN*, Boike L, Tong B, Brittain SM, McKenna JM, Tallarico JA, Schirle M, Maimone TJ[#], **Nomura DK**[#]. (2021) Chemoproteomics-enabled ligand discovery of covalent RNF114-based degraders that mimic natural product function. *Cell Chemical Biology* 28, 559-566. PMID 33513350 (*co-first authorship, [#] co-corresponding authorship)
16. Boike L*, Cioffi AG*, Majewski FC, Co J, Henning NJ, Jones MD, Liu G, McKenna JM, Tallarico JA, Schirle M, **Nomura DK**. (2021) Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC. *Cell Chemical Biology* 28, 4-13. PMID 32966806 (*co-first authorship)
17. Tong B, Belcher BP, **Nomura DK**, Maimone TJ (2021) Chemical investigations into the biosynthesis of the gymnastatin and dankastatin alkaloids. *Chemical Science* 12, 8884-8891. PMID 34257889

18. Biering SB, Van Dis E, Wehri E, Yamashiro LH, Nguyenla X, Dugast-Darzacq C, Graham TGW, Stroumza JR, Golovkine GR, Roberts AW, Fines DM, Spradlin JN, Ward CC, Bajaj T, Dovala D, Schulze Gahmen U, Bajaj R, Fox DM, Ott M, Murthy N, **Nomura DK**, Schaletzky J, Stanley SA (2021) Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2. *ACS Infectious Diseases* 7, 2337-2351. PMID 34129317
19. Kilinc S, Paisner R, Camarda R, Gupta S, Momcilovic O, Kohnz RA, L'Etoile ND, Perera RM, **Nomura DK**, Goga A (2021) Oncogene regulated release of extracellular vesicles. *Developmental Cell* 56, 1989-2006. PMID 34118203
20. Tharp KM, Higuchi-Sanabria R, Timblin GA, Ford B, Garzon-Coral C, Schneider C, Muncie JM, Stashko C, Daniele JR, Moore AS, Frankino PA, Homentcovschi S, Manoli SS, Shao H, Richards AL, Chen KH, Hoeve JT, Ku GM, Hellerstein M, **Nomura DK**, Saiko K, Gestwicki J, Dunn AR, Krogan NJ, Swaney DL, Dillin A, Weaver VM. (2021) Adhesion-mediated mechanosignaling forces mitohormesis. *Cell Metabolism* 33,1322-1341. PMID 34019840
21. Timblin GA, Tharp KM, Ford B, Winchenster JM, Wang J, Zhu S, Khan RI, Louie SK, Iavarone AT, ten Hoeve J, **Nomura DK**, Stahl A, Saijo K (2021) Mitohormesis reprograms macrophage metabolism to enforce tolerance. *Nature Metabolism* 3, 618-635. PMID 34031590
22. Moldavski O, Zushin P-JH, Berdan CA, Van Eijkeren RJ, Jiang X, Qian M, Ory DS, Covey SF, **Nomura DK**, Stahl A, Weiss EJ, Zoncu R (2021) 4 β -hydroxycholesterol is a pro-lipogenic factor that promotes SREBP1c expression and activity through Liver X-receptor. *Journal of Lipid Research*, 62, 100051. PMID 33631213
23. Cho H, Shen Q, Zhang LH, Okumura M, Kawakami A, Ambrose J, Sigoillot F, Miller HR, Gleim S, Cobos-Correa A, Wang Y, Piechon P, Roma G, Eggiman F, Moore C, Aspesi Jr. P, Mapa FA, Burks H, Ross NT, Krastel P, Hild M, Maimone TJ, Fisher DE, **Nomura DK**, Tallarico JT, Canham SM, Jenkins JL, Forrester WC (2021) CYP27A1 dependent anti-melanoma activity of limonoid natural products targets mitochondrial metabolism. *Cell Chemical Biology* 28, 1407-1419. PMID 33794192
24. Tomic I, Heppler LN, Egusquiaguirre SP, Boehnke N, Correa S, Costa DF, Grossman EA, Pal S, Richardson D, Ivanov AR, Haas-Kogan DA, **Nomura DK**, Hammond PT, Frank DA (2021) Lipidome-based targeting of STAT3-driven breast cancer cells using poly-L-glutamic acid-coated layer-by-layer nanoparticles. *Molecular Cancer Therapeutics* 20, 726-738. PMID 33536189

2020

25. Isobe Y, Okumura M, White R, McGregor LM, Brittain SM, Jones MD, Liang X, White R, Forrester W, McKenna JM, Tallarico JA, Schirle M, Maimone TJ*, **Nomura DK*** (2020) Manumycin polyketides act as molecular glues between UBR7 and P53. *Nature Chemical Biology* 16, 1189-1198. PMID 3257277 (*co-corresponding author)
26. Tong B*, Spradlin JN*, Novaes LFT, Zhang E, Hu X, Moeller M, Brittain SM, McGregor LM, McKenna JM, Tallarico JA, Schirle M, Maimone TJ#, **Nomura DK#**. (2020) A nimbolide-based kinase degrader preferentially degrades oncogenic BCR-ABL. *ACS Chemical Biology* 15, 1788-1794. PMID 32568522 (*co-first authorship; # co-corresponding authorship)
27. Tong B*, Luo M*, Xie Y, Spradlin JN, Tallarico JA, McKenna JM, Schirle M, Maimone TJ#, **Nomura DK#**. (2020) Bardoxolone Conjugation Enables Targeted Protein Degradation of BRD4. *Scientific Reports* 10, 15543. PMID 32968148 (*co-first authorship; # co-corresponding authorship)
28. Manford AG, Rodriguez-Perez F, Shih KY, Shi Z, Berdan CB, Choe M, Titov DV, **Nomura DK**, Rape M (2020) A cellular mechanism to detect and alleviate reductive stress. *Cell* 183, 46-61. PMID 32941802
29. Sponton CH, Hosonoro T, Taura J, Jedrychowski MP, Yoneshiro T, Wang Q, Takahashi M, Matsui Y, Ikeda K, Oguri Y, Tajima K, Shinoda K, Pradham R, Chen Y, Brown Z, Roberts LS, Ward CC, Taoka H, Yokohama Y, Watanabe M, Karasawa H, **Nomura DK**, Kajimura S (2020) The regulation of glucose and lipid homeostasis via PLTP as a mediator of BAT-liver communication. *EMBO Reports* 21, e49828. PMID 32672883
30. Ibars M, Maier MT, Yulyaningsih E, Perez L, Cheang R, Vihelmsson A, Louie SM, Wegner SA, Yuan X, Eltzschig HK, Hopf FW, **Nomura DK**, Koliwad SK, Xu AW (2020) Neuronal modulation of hepatic lipid accumulation induced by binge-like drinking. *American Journal of Physiology: Endocrinology and Metabolism* 318, E655-E666. PMID 32045262
31. Coles GL, Cristea S, Webber JT, Levin RS, Moss SM, He A, Sangodkar J, Hwang YC, Arand J, Drainas AP, Mooney NA, Demeter J, Spradlin JN, Mauch B, Le V, Shue YT, Ko JH, Lee MC, Kong C, **Nomura DK**, Ohlmeyer M, Swaney DL, Korgan N, Jackson PK, Narla G, Gordan JD, Shokat K, Sage J (2020) Unbiased

proteomic profiling uncovers a targetable GNAS/PKA/PP2A axis in small cell lung cancer stem cells. *Cancer Cell* 38, 129-143. PMID 32521271

2019

32. Chung CY-S*, Shin HR*, Berdan CA, Ford B, Ward CC, Olzmann JA, Zoncu R#, **Nomura DK**# (2019) Covalent targeting of the vacuolar H⁺-ATPase activates autophagy via mTORC1 inhibition. *Nature Chemical Biology* 15, 776-785. PMID 31285595 (*co-first authorship; #co-corresponding authorship)
33. Spradlin JN, Hu X, Ward CC, Brittain SM, Jones MD, Ou L, To M, Proudfoot A, Ornelas E, Woldegiorgis M, Olzmann JA, Bussiere DE, Thomas JR, Tallarico JA, McKenna JM, Schirle M, Maimone TJ*, **Nomura DK*** (2019) Harnessing the anti-cancer natural product nimbolide for targeted protein degradation. *Nature Chemical Biology* 15, 747-755. PMID 31209351 (*co-corresponding authors)
34. Ward CC, Kleinman JI, Chung CYS, Kim K, Petri Y, Lee PS, Thomas JR, Tallarico JA, McKenna JM, Schirle M, **Nomura DK** (2019) Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications. *ACS Chemical Biology* 14, 2430-2440. PMID 31059647
35. Berdan CA, Ho R, Lehtola HS, To M, Hu X, Huffman TR, Petri Y, Altobelli CR, Demeulenaere SG, Olzmann JA, Maimone TJ*, **Nomura DK*** (2019) Parthenolide covalently targets and inhibits focal adhesion kinase in breast cancer cells. *Cell Chemical Biology* 26, 1027-1035. PMID 31080076 (*co-corresponding authorship)
36. Ah Yong V, Berdan CA, Burke TP, **Nomura DK**, Welch MD (2019) A metabolic dependency for host isoprenoids in the obligate intracellular pathogen *Rickettsia parkeri* underlies a sensitivity to the statin class of host-targeted therapeutics. *mSphere* 4 (6), e00536-19. PMID 31722991
37. Bersuker K, Hendricks J, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, Bassik MC, **Nomura DK**, Dixon SJ, Olzmann JA (2019) The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature* 575, 688-692. PMID 31634900
38. Lim C-Y, Davis O, Shin H, Zhang J, Berdan CB, Jiang X, Coughlin JL, Ory D, Nomura DK, Zoncu R (2019) ER-lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signaling in Niemann-Pick type C. *Nature Cell Biology* 21, 1206-1218. PMID 31548609
39. Lee K, Yesilkamal AE, Wynne JP, Frakenberger C, Liu J, Yan J, Elbaz M, Rabe DC, Rustandy FD, Tiwari P, Grossman EA, Hart PC, Kang C, Sanderson SM, Andrade J, **Nomura DK**, Bonini MG, Locasale JW, Rosner MR (2019) Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. *Nature* 568, 254-258. PMID 30842661
40. Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, Porter LH, Niranjana B, Whitby ST, Lo J, Huang C, Schittenhelm RB, Anderson KE, Furic L, Wijayarathne PR, Matzaris M, Montgomery MK, Parpargiris M, Norden S, Febbraio M, Risbridger GP, Frydenberg M, **Nomura DK**, Taylor RA. (2019) Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. *Science Translational Medicine* 11(478):eaau5758. PMID 3078288
41. Herber CB, Krause WC, Wang L, Bayrer JR, Li A, Schmitz M, Fields A, Ford B, Zhang Z, Reid MS, **Nomura DK**, Nissenson RA, Correa SM, Ingraham HA (2019) Estrogen signaling in arcuate *Kiss1* neurons suppresses a sex-dependent female circuit promoting dense strong bones. *Nature Communications*, 10, 163. PMID 30635563
42. Magtanong L, Ko P-J, To M, Cao JY, Tarangelo AN, Ward CC, Cho KY, Patti GJ, **Nomura DK**, Olzmann JA, Dixon SJ (2019) Exogenous monounsaturated fatty acids suppress non-apoptotic cell death. *Cell Chemical Biology* 26, 420-432. PMID 30686757
43. Stazi G, Battistelli C, Piano V, Mazzone R, Marrocco B, Marchese S, Louie SM, Zwergel C, Antonini L, Patsilinakos A, Ragno R, Viviano M, Sbardella G, Ciogli A, Fabrizi G, Cirilli R, Strippoli R, Marchetti A, Tripodi M, **Nomura DK**, Mattevi A, Mai A, Valente S (2019) Development of alky glycerone phosphate synthase inhibitors: Structure-activity relationship and effects on ether lipids and epithelial-to-mesenchymal transition in cancer cells. *European Journal of Medicinal Chemistry* 163, 722-735. PMID 30576903
44. Volkmar N, Thezenas M-L, Louie SM, Juskiewicz S, **Nomura DK**, Hegde RS, Kessler BM, Christianson JC (2019) The ER membrane protein complex (EMC) promotes biogenesis of sterol-related enzymes maintaining cholesterol homeostasis. *Journal of Cell Science* 132, pii:jcs223453. PMID 30578317

2018

45. **Nomura DK** (2018) Virtual Issue on the Work of John Casida. *Chemical Research in Toxicology* 31, 637-638. PMID 30080400

46. **Nomura DK*** and Maimone TJ*. (2018) Target identification of bioactive covalently-acting natural products. *Current Topics in Microbiology and Immunology* 420, 351-374. PMID 30105423 (*co-corresponding authorship)
47. Counihan JL*, Wiggenhorn A*, Anderson KE, **Nomura DK**. (2018) Chemoproteomics-enabled covalent ligand screening reveals ALDH3A1 as a lung cancer target. *ACS Chemical Biology* 13, 1970-1977. (*co-first authors) PMID 300004670
48. Counihan JL, Grossman EA, **Nomura DK**. (2018) Cancer metabolism: current understanding and therapies. *Chemical Reviews* 118, 6893-6923. PMID 29939018
49. Long JZ, Roche AM, Berdan CA, Louie SM, Roberts AJ, Svensson KJ, Dou FY, Bateman LA, Mina AI, Deng Z, Jedrychowski MP, Lin H, Kamenecka T, Asara JM, Griffin PR, Banks AS, **Nomura DK**, Spiegelman BM. (2018) Ablation of PM20D1 reveals N-acyl amino acid control of metabolism and nociception. *Proceedings of the National Academy of Sciences, U.S.A.* 115, E6937-E6945. PMID 29967167
50. Fernandez RF, Kim SQ, Zhao Y, Foguth RM, Weera MM, Counihan JL, **Nomura DK**, Chester JA, Cannon JR, Ellis JM (2018) Acyl-CoA synthetase 6 enriches the neuroprotective omega-3 fatty acid DHA in the brain. *Proceedings of the National Academy of Sciences, U.S.A.* 115, 12525-12530. PMID 30327559
51. Zhou M, Ford B, Lee D, Huen K, Tran Y, Bradman A, Gunier R, Eskenazi B, **Nomura DK**, Holland NT (2018) Metabolomic markers of phthalate exposure in plasma and urine of pregnant women. *Frontiers in Public Health* 6, 298. PMID 30406068
52. Wallace M, Green CR, Roberts LS, Lee YM, McCarville J, Sanchez-Gurmaches J, Meurs N, Gengatharan JM, Hover J, Phillips SA, Ciaraldi TP, Guertin DA, Cabrales P, Ayres JS, **Nomura DK**, Loomba R, Metallo CM (2018) Enzyme promiscuity drives branched-chain fatty acid synthesis in adipose tissue. *Nature Chemical Biology* 14, 1021-1031. PMID 30327559
53. Van Daltsen KM, Hodapp S, Keskin A, Otto GM, Berdan CA, Higdon A, Cheunkarndee T, **Nomura DK**, Jovanovic M, Brar GA. (2018) Global proteome remodeling during ER stress involves Hac1-driven expression of long undecoded transcript isoforms. *Developmental Cell* 46, 219-235. PMID 30016623
54. Tam AB, Roberts LS, Chandra V, Rivera IG, **Nomura DK**, Forbes DJ, Niwa M. (2018) The UPR activator ATF6 responds to proteotoxic and lipotoxic stress by distinct mechanisms. *Developmental Cell* 46, 327-343. PMID 30086303
55. Patra KC, Kato Y, Mizukami Y, Widholz S, Boukhali M, Revenco I, Grossman EA, Ji F, Sadreyev RI, Liss AS, Screatton RA, Sakamoto K, Ryan DP, Mino-Kenudson M, Fernandez-del Castillo C, **Nomura DK**, Haas W, Bardeesy N. (2018) Mutant GNAS drives pancreatic tumorigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. *Nature Cell Biology* 20, 811-822. PMID 29941929
56. Maier MT, Vilhelmsson A, Louie SM, Vagena E, **Nomura DK**, Koliwad SK, Xu AW. (2018) Regulation of hepatic lipid accumulation and distribution by Agouti-related protein in male mice. *Endocrinology* 159, 2408-2420. PMID 29750244
57. Lin H, Long JZ, Roche AM, Svensson KJ, Dou F, Chang MR, Sruzenberg T, Ruiz C, Cameron MD, Novick SJ, Berdan CA, Louie SM, **Nomura DK**, Spiegelman BM, Griffin PR, Kamenecka TM. (2018) Discovery of hydrolysis-resistant isoindoline N-acyl amino acid analogs that stimulate mitochondrial respiration. *Journal of Medicinal Chemistry* 61, 3224-3230. PMID 29533650
58. Tomin T, Fritz K, Gindlhuber J, Waldherr L, Pucher B, Thallinger GG, **Nomura DK**, Schittmayer M, Birner-Gruenberger R. (2018) Deletion of adipose triglyceride lipase links triacylglycerol accumulation to a more aggressive phenotype in A549 lung carcinoma cells. *Journal of Proteome Research* 17, 1415-1425. PMID 29457907
59. Prasse C, Ford B, **Nomura DK**, Sedlak DL. (2018) Unexpected transformation of dissolved phenols to toxic dicarbonyls by hydroxyl radicals and UV light. *Proceedings of the National Academy of Sciences, USA.* 115, 2311-2316. PMID 29463747
60. Nnadi CI, Jenkins ML, Gentile DR, Bateman LA, Zaidman D, Ballus TE, **Nomura DK**, Burke JE, Shokat KM, London N. (2018) Novel K-Ras G12C switch-II covalent binders destabilize Ras and accelerate nucleotide exchange. *Journal of Chemical Information and Modeling* 57, 464-471. PMID 29320178
61. Gibeaux R, Acker R, Kitaoka M, Georgiou G, van Kruijsbergen I, Ford B, Marcotte EM, **Nomura DK**, Kwon T, Veenstra GJC, Heald R. (2018) Paternal chromosome loss and metabolic crisis contribute to hybrid inviability in *Xenopus*. *Nature* 553, 337-341. PMID 29320479
62. Bersuker K, Peterson CWH, To M, Sahl SJ, Savikhin V, Grossman EA, **Nomura DK**, Olzmann JA. (2018) A proximity labeling strategy provides insights into the composition and dynamics of lipid droplet proteomes. *Developmental Cell* 44, 97-112. PMID 29275994

2017

63. Lue JW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburgh KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, **Nomura DK**, Drake JM, Ritz A, Thomas GV. (2017) Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. *Genes and Development* 31, 2067-2084. PMID 29138276
64. De Leon JA, Qiu J, Nicolai CJ, Counihan JL, Barry KC, Xu L, Lawrence RE, Castellano BM, Zoncu R, **Nomura DK**, Luo Z-Q, Vance RE. (2017) Positive and negative regulation of the master metabolic regulator mTORC1 by two families of *Legionella pneumophila* effectors. *Cell Reports* 21, 2031-2038. PMID 29166595
65. Grossman E*, Ward CC*, Spradlin JN, Bateman LA, Huffman TR, Miyamoto DK, Kleinman JI, **Nomura DK**. (2017) Covalent ligand discovery against druggable hotspots targeted by anti-cancer natural products. *Cell Chemical Biology* 24, 1368-1376. PMID 28919038 (*co-first authorship)
66. Anderson KE, To M, Olzmann JA, **Nomura DK**. (2017) Chemoproteomics-enabled covalent ligand screening reveals a thioredoxin-caspase 3 interaction disruptor that impairs breast cancer pathogenicity. *ACS Chemical Biology* 12, 2522-2528. PMID 28892616
67. Chen T-C, Benjamin DI, Kuo T, Lee RA, Li M-L, Mar D, Costello DE, **Nomura DK**, Wang J-C. (2017) Glucocorticoid-Angiopoietin-like 4-Ceramide Axis induces insulin resistance. *Science Signaling* 10, eaai7905. PMID 28743803
68. Chomvong K, Benjamin DI, **Nomura DK**, Cate JH. Cellobiose consumption uncouples extracellular glucose sensing and glucose metabolism in *Saccharomyces cerevisiae*. *mBio* 8, e00855-17.
69. Nguyen TB, Louie SM, Daniele J, Tran Q, Dillin A, Zoncu R, **Nomura DK**, Olzmann JA. (2017) DGAT1-dependent lipid droplet biogenesis protects mitochondrial function during starvation-induced autophagy. *Developmental Cell* 42, 9-21. PMID 28697336
70. Ward CC, Kleinman J, **Nomura DK**. (2017) NHS-esters as versatile reactivity-based probes for mapping proteome-wide ligandable hotspots. *ACS Chemical Biology* 12, 1478-1483. PMID 28445029
71. Bateman LA[#], Nguyen TB[#], Roberts AM[#], Miyamoto DK, Ku W-M, Huffman TR, Petri Y, Heslin MJ, Contreras CM, Skibola CF, Olzmann JA*, **Nomura DK***. (2017) Chemoproteomics-enabled covalent ligand screen reveals a cysteine hotspot in Reticulon 4 that impairs ER morphology and cancer pathogenicity. *Chemical Communications* 53, 7234-7237. PMID 28352901 (#co-first authors; *co-corresponding author)
72. Roberts LS, Yan P, Bateman LA, **Nomura DK**. (2017) Mapping novel metabolic nodes targeted by anti-cancer drugs that impair triple-negative breast cancer pathogenicity. *ACS Chemical Biology* 12, 1133-1140. PMID 28248089
73. Bateman LA, Ku W-M, Heslin MJ, Contreras CM, Skibola CF, **Nomura DK**. (2017) ASS1 is an important metabolic regulator of colorectal cancer. *ACS Chemical Biology* 12, 905-911. PMID 28229591
74. Castellano, B.M., Thelen, A.M., Moldavski O, Feltes M, van der Welle R, Mydock-McGrane L, Jiang X, van Eijkeren RJ, Davis OB, Louie SM, Perera RM, Covey D, **Nomura DK**, Ory DS, Zoncu R. (2017) Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann Pick C1 signaling complex. *Science* 355, 1306-1311. PMID 28336668
75. Roberts AM, Miyamoto DK, Huffman TR, Bateman LA, Ives AN, Akopian D, Heslin MJ, Contreras CM, Rape M, Skibola CF, **Nomura DK**. (2017) Chemoproteomic screening of covalent ligands reveals UBA5 as a novel pancreatic cancer target. *ACS Chemical Biology* 12, 899-904. PMID 28186401
76. Counihan JL, Duckering M, Dalvie E, Ku W-m, Bateman LA, Fisher KJ, **Nomura DK**. (2017) Mapping proteome-wide reactivity of the widely used herbicide acetochlor in mice. *ACS Chemical Biology* 12, 635-642. PMID 28094496
77. Whang MI, Taveras RM, Benjamin DI, Kattah MG, Advincula R, **Nomura DK**, Debnath J, Malynn BA, Ma A. (2017) The ubiquitin binding protein TAX1BP mediates autophagosome induction and the metabolic transition of activated T cells. *Immunity* 46, 405-420. PMID 28314591
78. Anderton B, Camarda R, Balkrishnan S, Balakrishnan A, Kohnz RA, Lim L, Evason KJ, Momcilovic O, Kruttwig K, Huang Q, Xu G, **Nomura DK**, Goga A. (2017) MYC-driven inhibition of the glutamate-cysteine ligase promotes glutathione depletion in liver cancer. *EMBO Report* 18, 569-585. PMID 28219903
79. Ford B, Bateman LA, Gutierrez-Palominos L, Park R, **Nomura DK**. (2017) Mapping proteome-wide targets of glyphosate in mice. *Cell Chemical Biology* 24, 133-140. PMID 28132892
80. Ruby MA, Massart J, Hunerdosse DM, Schonke M, Correia JC, Louie SM, Ruas JL, Naslund E, **Nomura DK**, Zierath JR. (2017) Human carboxylesterase 2 reverses obesity-induced diacylglycerol accumulation and glucose intolerance. *Cell Reports* 18, 636-646. PMID 28099843

81. Roberts AM, Ward CC, **Nomura DK**. (2017) Activity-based protein profiling for mapping and pharmacologically interrogating proteome-wide ligandable hotspots. *Current Opinion in Biotechnology* 43, 25-33. PMID 27568596
82. To M, Peterson CWH, Roberts MA, Counihan JL, Wu TT, Forster MS, **Nomura DK**, Olzmann JA. (2017) Lipid disequilibrium disrupts ER proteostasis by impairing ERAD substrate glycan trimming and dislocation. *Molecular Biology of the Cell* 28, 270-284. PMID 27881664

2016

83. Kim H-E, Grant AR, Simic MS, Kohnz RA, **Nomura DK**, Durieux J, Riera CE, Sanchez M, Kapernick E, Wolff Suzanne, Dillin A (2016) Lipid biosynthesis coordinates a mitochondrial-to-cytosolic stress response. *Cell* 166, 1539-1552. PMID 27568596
84. Sogi K, Holsclaw C, Fragiadakis G, **Nomura DK**, Leary J, Bertozzi C. (2016) Biosynthesis and regulation of sulfomenaquinone, a metabolite associated with virulence in *Mycobacterium tuberculosis*. *ACS Infectious Diseases* 2, 800-806. PMID 27933784
85. Braverman J, Sogi KM, Benjamin D, **Nomura DK**, Stanley SA. (2016) HIF-1alpha is an essential mediator of IFA-gamma-dependent immunity to *Mycobacterium tuberculosis*. *Journal of Immunology* doi: 10.4049/jimmunol.1600266. PMID 27430718
86. Kohnz RA, Roberts, LS, DeTomaso D, Badyopadhyay S, Yosef N, **Nomura DK**. (2016) Protein sialylation regulates a gene expression signature that promotes breast cancer cell pathogenicity. *ACS Chemical Biology* 11, 2131-2139. PMID 27380425
87. Long JZ, Svensson KJ, Bateman LA, Lin H, Kamenecka T, Lokurkar IA, Lou J, Rao RR, Chang MT, Jedrychowski MP, Paolo J, Griffin PR, **Nomura DK***, Spiegelman BM* (2016) PM20D1 secretion by thermogenic adipose cells regulates lipidated amino acid uncouplers of mitochondrial respiration. *Cell* 166, 424-435. PMID 27374330 (*co-corresponding authorship)
88. Chomvong K, Bauer S, Benjamin DI, Li X, **Nomura DK**, Cate JHD. (2016) Bypassing the pentose phosphate pathway: Towards modular utilization of xylose. *Plos One* 11, e0158111. PMID 27336308
89. Louie SM, Grossman EA, Crawford LA, Ding L, Camarda R, Huffman TR, Miyamoto DK, Goga A, Weerapana E, **Nomura DK**. (2016) GSTP1 is a driver of triple-negative breast cancer cell metabolism and pathogenicity. *Cell Chemical Biology* 5, 567-578. PMID 27185638
90. Zhang J, Medina-Cleghorn D, Bernal-Mizrachi L, Bracci PM, Hubbard A, Conde L, Riby J, **Nomura DK**, Skibola C (2016) The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. *Oncoscience* 3, 31-41. PMID 26973858
91. Nikkanen J, Forsstrom S, Euro L, Paetau I, Kohnz RA, Wang L, Chilov D, Viinamaki J, Roivainen A, Marjamaki P, Liljenback H, Ahola S, Buzkova J, Terzioglu M, Khan NA, Pirnes-Karhu S, Paetau A, Lonqvist T, Sajantila A, Isohanni P, Tyynismaa H, **Nomura DK**, Battersby B, Velagapudi V, Carroll CJ, Suomalainen A (2016) Mitochondrial DNA replication defects disturb cellular dNTP pools and remodel one-carbon metabolism. *Cell Metabolism* 23, 635-648. PMID 26924217
92. **Nomura DK**, Casida JE (2016) Lipases and their inhibitors in health and disease. *Chemico-Biological Interactions* 259, 211-222. PMID 27067293
93. Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, **Nomura DK**, Goga A. (2016) Inhibition of fatty-acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. *Nature Medicine* 22, 427-432. PMID 26950360.
94. Saghatelian A, **Nomura DK**, Weerapana E (2016) Omics: The maturation of chemical biology. *Current Opinions in Chemical Biology* 30: v-vi. PMID 26739665
95. Counihan JC, Ford B, **Nomura DK**. (2016) Mapping Proteome-Wide Interactions of Reactive Chemicals using Chemoproteomic Platforms. *Current Opinions in Chemical Biology* 30, 68-76. PMID 26647369

2015

96. Medina-Cleghorn D, Bateman LA, Ford B, Heslin A, Fisher KJ, Dalvie ED, **Nomura DK**. (2015) Mapping proteome-wide targets of environmental chemicals using reactivity-based chemoproteomic platforms. *Chemistry and Biology* 22, 1394-1405. PMID26496688
97. Piano V[#], Benjamin DI[#], Valente S, Nenci S, Mai A, Aliverti A, **Nomura DK***, Mattevi A*. (2015) Discovery of inhibitors for the ether lipid-generating enzyme AGPS as anti-cancer agents. *ACS Chemical Biology* 10, 2589-2597. PMID 26322624 ([#]co-first authors; * co-corresponding authors).
98. Queiroz A, Medina-Cleghorn D, Marjanovic O, **Nomura DK**, Riley LW. (2015) Comparative metabolic profiling of *Mycobacterium tuberculosis*: cell wall lipid reorganization as a virulence factor. *Pathogens and Disease* 73, ftv066. PMID26319139.

99. Sanchez-Alavez M, Nguyen W, Mori S, Moroncini G, Viader A, **Nomura DK**, Cravatt BF, Conti B. (2015) Monoacylglycerol lipase regulates fever response. *Plos One* 10, e0134437. PMID: 26287872.
100. Kohnz RA, Mulvihill MM, Chang JW, Hsu K-L, Sorrentino A, Cravatt BF, Bandyopadhyay S, Goga A, **Nomura DK**. (2015) Activity-based protein profiling of oncogene-driven changes in metabolism reveals PAFAH1B2 and 1B3 as broad-spectrum cancer therapy targets. *ACS Chemical Biology* 10, 1624-1630. PMID: 25945974.
101. Benjamin DI, Li DS, Lowe, W, Heuer T, Kemble G, **Nomura DK**. (2015) Diacylglycerol metabolism and signaling is a predictive and driving force underlying FASN inhibitor sensitivity in cancer cells. *ACS Chemical Biology* 10, 1616-1623. PMID: 25871544
102. Rashidian J, Le Scolan E, Ji X, Mulvihill MM, **Nomura DK**, Luo K. (2015) Ski regulates Hippo and TAZ signaling to suppress breast cancer progression. *Science Signaling* 10, ra14. PMID: 25670202
103. Anderson CM, Kazantzis M, Wang J, Venkatraman S, Goncalves RLS, Quinlan CL, Ng R, Jastroch, M, Benjamin DI, Nie B, Herber C, Van A-AN, Park MK, Yun D, Chan K, Yu A, Vuong P, Febbraio M, **Nomura DK**, Napoli JL, Brand MD, Stahl A. (2015) Dependence of brown adipose tissue function on CD36-mediated coenzyme Q uptake. *Cell Reports* 10, 505-515. PMID 25620701
104. Chang JW, Zuhl AM, Speers AE, Niessen S, Brown SJ, Mulvihill MM, Fan YC, Spicer TP, Southern M, Scampavia L, Fernandez-Vega V, Dix MM, Cameron MD, Hodder PS, Rosen H, **Nomura DK**, Kwon O, Hsu K-L, Cravatt BF. (2015) A selective inhibitor of platelet-activating factor acetylhydrolases 1b2 and 1b3 that impairs cancer cell survival. *ACS Chemical Biology* 10, 925-932. PMID: 25602368

2014

105. Lysenko LV, Kim J, Henry C, Tyrtysnaia A, Kohnz RA, Madamba F, Simon GM, Kleschevnikova NE, **Nomura DK**, Ezekowitz RAB, Kleschevnikov AM. (2014) Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in aged Ts65Dn mice, a model of Down Syndrome. *Plos One* 9, e114521. PMID: 25474204.
106. Valdearcos M, Robblee M, Benjamin DI, **Nomura DK**, Xu AW, Koliwad SK. (2014) Microglia Dictate the Impact of Saturated Fat Consumption on Hypothalamic Inflammation and Neuronal Function. *Cell Reports* 9, 1-15. PMID: 25497089
107. Hunerdosse D, Morris PJ, Miyamoto DK, Fisher KJ, Bateman LA, Ghazaleh J, Zhong S, **Nomura DK**. (2014) Chemical Genetics Screening Reveals KIAA1363 as a Cytokine-Lowering Target. *ACS Chemical Biology* 9, 2905-2913. PMID: 25343321.
108. Medina-Cleghorn D, **Nomura DK**. (2014) Exploring metabolic pathways and regulation through functional chemoproteomic and metabolomic platforms. *Chemistry & Biology* 21, 1171-1184. PMID: 25237861.
109. Mulvihill MM, **Nomura DK**. (2014) Metabolomic Strategies to Map Functions of Metabolic Pathways. *AJP Metabolism and Endocrinology* 307, E237-E244. PMID: 24918200
110. Latimer LN, Lee MR, Medina-Cleghorn D, Kohnz RA, **Nomura DK**, Dueber JE. (2014) Employing a combinatorial expression approach to characterize xylose utilization in *Saccharomyces cerevisiae*. *Metabolic Engineering* 25, 20-29. PMID: 24930894.
111. Mulvihill MM, Benjamin DI, LeScolan E, Ji X, Shieh A, Green M, Narasimhalu T, Morris PJ, Luo K, **Nomura DK**. (2014) Metabolic Profiling Reveals PAFAH1B3 as a critical driver of breast cancer pathogenicity. *Chemistry & Biology* 21, 831-840. PMID: 24954006
112. Benjamin DI, Louie S, Mulvihill MM, Kohnz RA, Li DS, Chan LG, Sorrentino A, Bandyopadhyay S, Cozzo A, Ohiri A, Goga A, Ng-SW, **Nomura DK**. (2014) Inositol phosphate recycling regulates glycolytic and lipid metabolism that drives cancer aggressiveness. *ACS Chemical Biology* 20, 1340-1350. PMID: 24738946
113. Kohnz RK, **Nomura DK**. (2014) Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. *Chemical Society Reviews* 43, 6859-6869. PMID: 24676249
114. Morris PJ*, Medina-Cleghorn D*, Heslin A, King S, Orr J, Krauss RM, **Nomura DK**. (2014) Organophosphorus flame retardants inhibit specific liver carboxylesterases and cause serum hypertriglyceridemia. *ACS Chemical Biology* 9, 1097-1103. (*authors contributed equally to the work) PMID: 24597639
115. Hunerdosse D, **Nomura DK**. (2014) Activity-based proteomic and metabolomic approaches for understanding metabolism. *Current Opinion in Biotechnology* 28C, 116-126. PMID 24594637

116. Poole D, Lee M, Tso P, Bunnett N, Yo S, Lieu T, Shiu A, Wang J-C, **Nomura DK**, and Aponte GW. (2014) Feeding dependent activation of enteric cells and sensory neurons by lymphatic fluid: evidence for a neurolymphocrine system. *AJP-Gastrointestinal and Liver Physiology* 306, G686-G698. PMID: 24578341
117. Dominguez E, Galmozzi A, Chang JW, Hsu K-L, Pawlak J, Li W, Godio C, Thomas J, Partida D, Niessen S, O'Brien PE, Russell AP, Watt MJ, **Nomura DK**, Cravatt BF, Saez E. (2014) Integrated phenotypic screening and activity-based proteomics defines a role for carboxylesterase 3 in obesity and diabetes. *Nature Chemical Biology* 10, 113-121. PMID: 24362705
118. Medina-Cleghorn D, Heslin A, Morris PJ, Mulvihill MM, **Nomura DK**. (2014) Multidimensional profiling platforms reveal metabolic dysregulation caused by organophosphorus pesticides. *ACS Chemical Biology* 9, 423-432. PMID: 24205821

2013

119. **Nomura DK**, Cravatt BF. (2013) Lipid Metabolism in Cancer. *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids* 1831, 1497-1498. PMID: 23921253
120. Benjamin DI, Cozzo A, Ji X, Roberts LS, Louie SM, Luo K, **Nomura DK**. (2013) The ether lipid generating enzyme AGPS alters the balance of structural and signaling lipids that fuel cancer pathogenicity. *Proceedings of the National Academy of Sciences, USA* 110, 14912-14917. PMID: 23980144
121. Louie SM*, Roberts LS*, Mulvihill MM, Luo K, **Nomura DK**. (2013) Cancer cells incorporate and remodel exogenous fatty acids into structural and oncogenic signaling lipids. *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids* 1831, 1566-1572. PMID: 23872477 (* authors contributed equally to the work)
122. Louie SM, Roberts LS, **Nomura DK**. (2013) Mechanisms linking obesity and cancer. *Biochimica et Biophysica Acta—Molecular and Cell Biology of Lipids* 1831, 1499-1508. PMID: 23470257
123. Medina-Cleghorn D, **Nomura DK**. (2013) Chemical Approaches to Study Metabolic Networks. *Pflugers Archive* 465,427-440. PMID: 23296751
124. Cao Z, Mulvihill MM, Mukhopadhyay P, Xu H, Erdelyi K, Hao E, Holovac E, Hasko G, Cravatt BF, **Nomura DK**[#], Pal Pacher[#]. (2013) Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. *Gastroenterology* 144, 808-817. PMID: 23295443 (# co-corresponding authors)
125. Mulvihill MM, **Nomura DK**. (2013) Therapeutic Potential of Monoacylglycerol Lipase Inhibitors. *Life Sciences* 92, 492-497. PMID: 23142242

2012

126. Morrison BE, Garibaldi Marcondes MC, **Nomura DK**, Sanchez-Alavez M, Saar I, Bartfai T, Maher P, Sugama S, Conti B. (2012) IL-13R α 1 expression in dopaminergic neurons contributes to their oxidative stress-mediated loss following chronic systemic treatment with LPS. *Journal of Immunology* 189, 5498-5502. PMID: 23169588
127. Benjamin DI, Cravatt BF, **Nomura DK**. (2012) Global Profiling Strategies towards Mapping Dysregulated Metabolic Pathways in Cancer. *Cell Metabolism* 16, 565-567. PMID: 23063552
128. Piro JR, Benjamin DI, Duerr JM, Pi YQ, Gonzales C, Schwartz JW, **Nomura DK**[#], Samad TA[#]. (2012) A Dysregulated Endocannabinoid-Eicosanoid Network Supports Pathogenesis in a Mouse Model of Alzheimer's Disease. *Cell Reports* 1, 617-623. PMID: 22813736 (# co-corresponding author)

2011

129. **Nomura DK**[#], Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, Ward AM, Hahn YK, Lichtman AH, Conti B, Cravatt BF[#]. (2011) Endocannabinoid hydrolysis generates brain eicosanoids that promote neuroinflammation. *Science* 334, 809-813. PMID: 22021672 (# co-corresponding author)
130. Ruby MA, **Nomura DK**, Hudak CSS, Barber A, Casida JE, Krauss RM. (2011) Overactive endocannabinoid signaling induces hepatic steatosis, insulin resistance, and global transcriptional changes. *Plos One* 6, e26415. PMID: 22073164

Undergraduate/Graduate/Postdoctoral Work (2002-2011)

131. **Nomura DK**[#], Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ, Hoover HH, Cravatt BF[#]. (2011) Monoacylglycerol lipase exerts bidirectional control over endocannabinoid and fatty acid pathways

- to support prostate cancer pathogenesis. *Chemistry & Biology* 18, 848-856. PMID: 21802006 (# co-corresponding author)
132. Ramesh D, Ross GR, Schlosburg JE, Abdullah RA, Kinsey SG, Long JZ, **Nomura DK**, Sim-Selley LJ, Cravatt BF. (2011) Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated withdrawal symptoms in mice. *Journal of Pharmacology and Experimental Therapeutics* 339, 173-185. PMID: 21719468
 133. Kinsey SG, **Nomura DK**, O'Neal ST, Long JZ, Cravatt BF, Lichtman AH. (2011) Inhibition of monoacylglycerol lipase (MAGL) attenuates NSAID-induced gastric hemorrhages in mice. *Journal of Pharmacology and Experimental Therapeutics* 338, 795-802. PMID: 21659471
 134. Chang JW, **Nomura DK**, Cravatt BF. (2011) A potent and selective inhibitor of KIAA1363/AADACL1 that impairs prostate cancer pathogenesis. *Chemistry & Biology* 18, 476-484. PMID: 21513884
 135. Ahn K, Smith SE, Liimata MB, Sadagopan N, Dudley D, Young T, Wren P, Zhang Y, Swaney S, Van Becelaere K, Blankman JL, **Nomura DK**, Bhattachar SN, Stif C, Nomanbhoy TK, Weerapana E, Johnson DS, Cravatt BF. (2011) Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective FAAH inhibitor that reduces inflammatory and noninflammatory pain. *Journal of Pharmacology and Experimental Therapeutics* 338, 114-124. PMID: 21505060
 136. **Nomura DK**[#], Casida JE[#]. (2011) Activity-based protein profiling of organophosphorus and thiocarbamate pesticides reveals multiple secondary targets in the mammalian nervous system. *Journal of Agricultural and Food Chemistry* 59, 2808-2815. PMID: 21341672 (# co-corresponding author)
 137. Nicolaou KC, Sanchini S, Sarlah D, Lu G, Wu R, **Nomura DK**, Cravatt BF, Cubitt B, de la Torre JC, Hessell AJ, Burton DR. (2011) Design, synthesis and biological evaluation of a biyouyanagin compound library. *Proceedings of the National Academy of Sciences, USA* 108, 6715-6720. PMID: 21245351
 138. Bachovchin DA, Mohr JT, Speers AE, Wang C, Berlin JM, Spicer TP, Fernandez-Vega V, Chase P, Hodder PS, Schürer, **Nomura DK**, Rosen H, Fu GC, Cravatt BF. (2011) Academic cross-fertilization by public screening yields a remarkable class of protein phosphatase methylesterase-1 inhibitors. *Proceedings of the National Academy of Sciences, USA* 108, 6811-6816. PMID: 21398589
 139. Kopp F, Komatsu T, **Nomura DK**, Trauger SA, Thomas JR, Simon GM, Cravatt BF. (2010) The glycerophospho-metabolome and its influence on amino acid homeostasis by brain metabolomics of GDE1(-/-) mice. *Chemistry & Biology* 17, 831-840. PMID: 20797612
 140. Schlosburg JE, Blankman JL, Long JZ, **Nomura DK**, Nguyen PT, Ramesh D, Kinsey SG, Booker L, Burston JK, Wise LE, Ghosh S, Selley DE, Sim-Selley LJ, Liu Q, Cravatt BF, Lichtman AH. (2010) Sustained inactivation of monoacylglycerol lipase produces functional antagonism of the brain endocannabinoid system. *Nature Neuroscience* 13, 1113-1119. PMID: 20729846
 141. **Nomura DK**, Dix MM, Cravatt BF. (2010) Chemoproteomic Approaches for Biochemical Pathway Discovery in Cancer. *Nature Reviews Cancer* 10, 630-638. PMID: 20703252
 142. **Nomura DK**, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF. (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. *Cell* 140, 49-61. PMID: 20079333
 143. Long JZ, **Nomura DK**, Vann RE, Walentiny DM, Booker L, Jin X, Burston JJ, Sim-Selley LJ, Lichtman AH, Wiley JL, Cravatt BF. (2009) Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. *Proceedings of the National Academy of Sciences, USA* 106, 20270-20275. PMID: 19918051
 144. Long JZ, **Nomura DK**, Cravatt BF. (2009) Mechanistic characterization of selective monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. *Chemistry & Biology* 16, 744-753. PMID: 19635411
 145. Ruby M*, **Nomura DK***, Hudak CS, Mangravite LM, Chiu S, Casida JE, Krauss RM. (2008) Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. *Proceedings of the National Academy of Sciences, USA* 105, 14561-14566. PMID: 18794527 (* co-first author)
 146. **Nomura DK**, Ward AM, Hudak CS, Burston JJ, Issa RS, Fisher KJ, Abood ME, Wiley JL, Lichtman A, Casida JE. (2008) Monoacylglycerol lipase regulates 2-arachidonoylglycerol action and arachidonic acid levels. *Bioorganic Medicinal Chemistry Letters* 18, 5875-5878. PMID: 18752948
 147. Casida JE, **Nomura DK**, Vose SC, Fujioka K. (2008) Organophosphate-Sensitive Lipases Modulate Brain Lysophospholipids, Ether Lipids and Endocannabinoids. *Chemico-Biological Interactions* 175, 355-64. PMID: 18495101
 148. **Nomura DK**, Blankman JL, Simon GM, Fujioka K, Issa RS, Ward AM, Cravatt BF, Casida JE. (2008) Activation of the endocannabinoid system by organophosphorus nerve agents. *Nature Chemical Biology* 4, 373-378. PMID: 18438404

149. **Nomura DK**, Fujioka K, Issa RS, Ward AM, Cravatt BF, Casida JE. (2008) Dual Roles of Brain Serine Hydrolase KIAA1363 in Ether Lipid Metabolism and Organophosphate Detoxification. *Toxicology and Applied Pharmacology* 228, 42-482. PMID: 18154358
150. **Nomura DK**, Durkin KA, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2006) Serine Hydrolase KIAA1363: Toxicological and Structural Features with Emphasis on Organophosphate Interactions. *Chemical Research in Toxicology* 19, 1142-1150. PMID: 16978018
151. Quistad GB, Liang SN, Fisher KJ, **Nomura DK**, Casida JE. (2006) Each Lipase has a Unique Sensitivity Profile for Organophosphorus Inhibitors. *Toxicological Sciences* 91,166-172. PMID: 16449251
152. **Nomura DK**, Leung D, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2005) A Brain Detoxifying Enzyme for Organophosphorus Nerve Poisons. *Proceedings of the National Academy of Sciences, USA* 102, 6195-6200. PMID: 15840715
153. Segall Y, Quistad GB, Sparks SE, **Nomura DK**, Casida JE. (2003) Toxicological and Structural Features of Organophosphorus and Organosulfur Cannabinoid CB1 Receptor Ligands. *Toxicological Sciences* 76, 131-137. PMID: 12944568
154. Segall Y, Quistad GB, **Nomura DK**, Casida JE. (2003) Arachidonylsulfonyl Derivatives as Cannabinoid CB1 Receptor and Fatty Acid Amide Hydrolase Inhibitors. *Bioorganic Medicinal Chemistry Letters* 13,3301-3303. PMID: 12951114
155. Quistad GB, **Nomura DK**, Sparks SE, Segall Y, Casida JE. (2002) Cannabinoid CB1 Receptor as a Target for Chlorpyrifos Oxon and Organophosphorus Pesticides. *Toxicology Letters* 135, 89-93. PMID: 12243867
156. Quistad GB, Sparks SE, Segall Y, **Nomura DK**, Casida JE. (2002) Selective Inhibitors of Fatty Acid Amide Hydrolase Relative to Neuropathy Target Esterase and Acetylcholinesterase: Toxicological Implications. *Toxicology and Applied Pharmacology* 179, 57-63. PMID: 11884237

Patents

1. McKenna J, **Nomura DK**, Toriki E, Papatzimas J, Dovala D, Hesse M, Nishikawa K. Molecular Glue Degradation Compounds and Uses Thereof. Provisional Patent Application filed October 21, 2022.
2. **Nomura DK**, Henning NJ, Spradlin JN, Ward CC, McKenna JM, Schirle M, Tallarico JA, Hesse M, Dovala D. Deubiquitinase Targeting Chimeras and Related Methods. PCT application filed.
3. Rape M, **Nomura DK**, Henning N, Manford A. FEM1B protein binding agents and uses thereof. PCT application filed.
4. **Nomura DK**, Cioffi A, Schirle M, Boike L, Tallarico JA, McKenna JM, Liu G. MYC inhibitors and uses thereof. Provisional patent application filed.
5. **Nomura DK**, Zoncu R, Chung YSC, Shin H, Canham S. mTORC1 inhibitors for Activating autophagy. PCT application WO2020146779.
6. **Nomura DK**, Roberts AM, Bateman LA, Miyamoto DK, Huffman TR, Ward CC. Compositions and methods for modulating UBA5. PCT application WO2018144869A1.
7. **Nomura DK**, Zoncu R, Roberts AM, Cho, KF, Chung YSC, Shin J, Croze B. mTORC1 modulators; US20190112268A1.
8. **Nomura DK**, Zoncu R, Ward C, Fung SK, Varma CK, Fontaine B. Methods and compounds for targeted autophagy. PCT Application WO2019183600A1.
9. Spradlin J, Ward CC, **Nomura DK**, Schirle M, Tallarico JA, McKenna JM, Maimone TJ, Hu X. Covalent targeting of E3 ligases. PCT Application WO2020076996A1.
10. **Nomura DK**, Anderson KE. Thioredoxin modulators and uses thereof. PCT application WO2018175958A1.
11. **Nomura DK**, Roberts LS, Ward CC. Compositions for treating breast cancer. PCT WO2018148598A1.
12. **Nomura DK**, Grossman EA, Ward CC, Bateman LA, Huffman TR, Miyamoto DK, Spradlin JL. Compositions and methods for modulating ppp2r1a. US20200054651A1.
13. **Nomura DK**, Olzmann JA, Bateman LA, Nguyen TB, Miyamoto DK, Huffman TR, Roberts AM. Compositions and methods for inhibiting Reticulon 4. PCT application WO2018144870A8.
14. Bachovchin D, Chang JW, Cravatt BF, Li W, Moellering RE, **Nomura DK**. Anti-cancer serine hydrolase inhibitory carbamates. US9249128B2.

15. Cravatt BF, Long JZ, Li W, **Nomura DK**. Methods and Compositions Related to Targeting Monoacylglycerol Lipase. US8772318B2.

Abstracts/meetings/invited talks

1. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Japan Chemical Biology meeting, Osaka, Japan.
2. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Princeton University Department of Chemistry seminar series, Princeton, NJ.
3. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Hanson Wade Molecular Glue Degradation Summit, Boston, MA.
4. Invited Speaker: **Nomura DK** (2023) Reimagining Druggability using Chemoproteomic Platforms. Harvard Medical School Department of Cell Biology student invite, Boston, MA.
5. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. University of Illinois, Urbana-Champaign, 18th Annual CBI TP Symposium for the Chemistry-Biology Interface Training Program (CBITP), Urbana-Champaign, Illinois.
6. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. FASEB Ubiquitin and Ubiquitin-like proteins conference, Boston, MA.
7. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. Applied Pharmaceutical Chemistry Symposium, Cambridge, MA.
8. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. 2nd Metabolism in Health and Disease, Cancun, Mexico.
9. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. 2nd Induced Proximity-Based Drug Discovery Summit, Boston, MA.
10. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. American Association of Cancer Research meeting, New Orleans, LA.
11. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. UC Santa Cruz Department of Chemistry seminar series, Santa Cruz, CA.
12. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. RSC Fragment based drug discovery, Cambridge, UK.
13. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. University of Pennsylvania, Department of Chemistry, Virtual.
14. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. Induced Proximity Targeting and Undruggables Conference, Boston, MA.
15. Invited Speaker: **Nomura DK** (2022) Reimagining Druggability using Chemoproteomic Platforms. Johns Hopkins University, Chemical Biology Interface Program student invite, Baltimore, Maryland.
16. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Pacific Chem Conference, Virtual.
17. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. NYAS Targeted Protein Degradation: From Drug Discovery to the Clinic, Virtual
18. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at Emory University, Atlanta, GA.
19. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at University of Southern California, Los Angeles, CA.
20. Keynote Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. International Chemical Biology Society meeting, Virtual
21. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. LMU Munich Organic Chemistry seminar, Virtual
22. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at UC Irvine, Irvine, CA.
23. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Research seminar at University of Minnesota, Minneapolis, Minnesota.
24. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Discovery on Target meeting, Cambridge, MA
25. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Novartis: Frontiers of Science and Medicine Institutional Lecture, Cambridge, MA

26. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Institute Chemical Biology Symposium, Virtual
27. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. European Targeted Protein Degradation meeting, Virtual
28. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Vertex research seminar, Boston, MA
29. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Induced Proximity-Based Drug Discovery Summit, Hanson Wade, Virtual.
30. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. BioTechne Symposium: Advances in Targeted Protein Degradation, Virtual
31. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Ligase Targeting Drug Development, Hanson Wade, Virtual.
32. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. AACR meeting Chemistry in Cancer Research Town Hall, Virtual
33. Invited Speaker: **Nomura DK** (2021) Developing Coronavirus Anti-Viral Drugs. Center for Emerging and Neglected Diseases Symposium, Virtual.
34. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Helmholtz Drug Discovery Conference Speaker, Virtual.
35. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Rutgers University seminar speaker, Virtual.
36. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. North American Protein Degradation Congress meeting, Kisaco Research, Virtual.
37. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Targeted Protein Degradation & PROTAC symposium, Oxford Global, Virtual.
38. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. Stanford University, Department of Chemistry, Virtual.
39. Invited Speaker: **Nomura DK** (2021) Reimagining Druggability using Chemoproteomic Platforms. SLAS International Conference, Virtual.
40. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. UCSF Cancer Center, Virtual.
41. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Dana Farber Cancer Center Targeted Protein Degradation Seminar Series, Virtual.
42. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Janssen, Virtual.
43. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Oregon Health Sciences University, Virtual.
44. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. 3rd Annual Targeted Protein Degradation Meeting, Virtual.
45. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. 18th Annual Discovery on Target Conference, Virtual.
46. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Northwestern University Department of Chemistry, Virtual.
47. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Pfizer, Virtual.
48. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Transcription Factor Drug Development Conference, Virtual.
49. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Seminar at Cygnal Therapeutics, Virtual.
50. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. Natural Products Symposium at the New York Academy of Sciences, Virtual.
51. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. North American Targeted Degradation Summit. San Diego, CA.
52. Invited Speaker: **Nomura DK** (2020) Reimagining Druggability using Chemoproteomic Platforms. The Mark Foundation for Cancer Research Induced Proximity Meeting, New York, New York
53. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. MIT/Broad Institute Chemical Biology seminar series, Cambridge, MA

54. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Seminar at Calico, South San Francisco, CA
55. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. California Institute of Technology Chemical Biology seminar series, Pasadena, CA
56. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. UT San Antonio, San Antonio, TX.
57. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Harvard University Chemistry and Chemical Biology seminar speaker, Cambridge, MA
58. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Memorial Sloan Kettering Cancer Center, New York, NY.
59. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Bayer Life Science Workshop: Chemical Biology—Jointly Exploring New Frontiers, Berlin, Germany
60. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. 2nd Targeted Protein Degradation Summit meeting, Boston, MA
61. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Northwestern University, Chicago, IL.
62. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. American Chemical Society meeting, Targeted Protein Degradation session, San Diego, CA.
63. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Janssen Pharmaceuticals seminar speaker, Springhouse, Pennsylvania.
64. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Targeted Drug Discovery Summit, Boston, MA.
65. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. 60th International Conference on the Biosciences of Lipids, Tokyo, Japan.
66. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Bioorganic Chemistry Gordon Research Conference, Andover, NH.
67. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Novartis Institutes for BioMedical Research, Basel, Switzerland.
68. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. European Targeted Protein Degradation meeting, Basel, Switzerland
69. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Cayman Chemical Biology Symposium at the University of Michigan, Ann Arbor, Ann Arbor, MI.
70. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Yale Chemical Biology symposium, New Haven, CT.
71. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. World Molecular Engineering Network meeting, Cabo San Lucas, Mexico.
72. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. American Cancer Society meeting, Orlando, FL.
73. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Structural Genomics Consortium Targeted Protein Degradation meeting, Toronto, CA.
74. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Mark Foundation for Cancer Research Symposium, New York, NY.
75. Invited Speaker: **Nomura DK** (2019) Reimagining Druggability using Chemoproteomic Platforms. Medicinal and Bioorganic Chemistry Foundation meeting, Steamboat, CO.
76. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. 1st Targeted Protein Degradation Summit meeting, Boston, MA
77. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Merck and Co. Organic Chemistry Seminar Series, Kenilworth, NJ.
78. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Caltech Department of Chemistry, Pasadena, California.
79. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. EMBO Enzymes and Catalysis meeting, Pavia, Italy.
80. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. City of Hope Research Institute, Los Angeles, CA
81. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Structural Genomics Consortium on Target 2035. Berlin, Germany

82. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. BASF Metanomics, Berlin, Germany
83. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Pharmaron, Beijing, China.
84. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. BASF-CARA Symposium, Santa Barbara, CA.
85. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Cambridge Healthtech Institute's 17th Annual World Preclinical Congress, Boston, MA.
86. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. ACS National Medicinal Chemistry Symposium, Nashville, TN.
87. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Merck, South San Francisco, CA.
88. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. 2018 San Antonio Drug Discovery Symposium, San Antonio, TX.
89. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. AACR meeting, Chicago, IL.
90. Invited Speaker and Session Chair: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. ASBMB meeting, San Diego, CA.
91. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Agios, Cambridge, MA.
92. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. Astrazeneca, Waltham, MA.
93. Invited Speaker: **Nomura DK** (2018) Redefining Druggability and Toxicology using Chemoproteomic Platforms. University of California, Riverside, Riverside, CA.
94. Invited Speaker: **Nomura DK** (2018) Redefining Druggability using Chemoproteomic Platforms. Tumor Metabolism Keystone meeting, Snowbird, Utah.
95. Invited Speaker: **Nomura DK** (2017) Redefining Toxicology and Druggability using Chemoproteomic Platforms. Superfund Research Program meeting, Philadelphia, Pennsylvania.
96. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. Tufts University Medical School, Boston, MA.
97. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. University of Virginia, Charlottesville, VA.
98. Invited Speaker and Wendell Griffith Lecturer: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. St Louis University, St. Louis, MO.
99. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. AACR Advances in Breast Cancer Meeting, Hollywood, CA.
100. Invited Speaker: **Nomura DK** (2017) Redefining Druggability using Chemoproteomic Platforms. Austrian Proteomics Association meeting, Graz, Austria.
101. Invited Speaker: **Nomura DK** (2017) Chemoproteomic Platforms for Mapping Druggable Hotspots in Disease. Enzymes, Coenzymes, & Metabolic Pathways Gordon Conference. Waterville Valley, NH.
102. Invited Speaker: **Nomura DK** (2017) Chemoproteomic and Metabolomic Platforms for Mapping Drivers of Disease. American Diabetes Association meeting. San Diego, CA.
103. Invited Speaker: **Nomura DK** (2017) Chemoproteomic Platforms for Mapping Druggable Hotspots in Disease. Royal Society of Chemistry Chemical Biology Symposium. London, UK.
104. Invited Speaker: **Nomura DK** (2017) Chemoproteomic Platforms for Mapping Druggable Hotspots in Disease. World Molecular Engineering Network conference, San Jose Del Cabo, Mexico.
105. Invited Speaker: **Nomura DK** (2017) Using Chemoproteomic and Metabolomic Platforms to Map Drivers of Human Disease, UCSF Breast Oncology Program Seminar, San Francisco, CA.
106. Invited Speaker: **Nomura DK** (2017) Using Chemoproteomic and Metabolomic Platforms to Map Drivers of Human Disease, Cold Spring Harbor Laboratory, Chemistry and Metabolism Symposium, Cold Spring Harbor, NY.
107. Invited Speaker: **Nomura DK** (2017) Using Chemoproteomic and Metabolomic Platforms to Map Drivers of Human Disease, Johns Hopkins Medical School, Department of Biological Chemistry, Baltimore, Maryland.
108. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, The University of Sydney Charles Perkin Centre, Sydney, Australia.

109. Keynote Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Third Australian Lipids Meeting, Melbourne, Australia.
110. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, University of Georgia, Athens, Georgia.
111. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, UCSD Metabolomics Symposium, La Jolla, CA.
112. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Oregon Health State University, Portland, Oregon.
113. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Amgen South San Francisco, CA
114. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Drug Discovery and Toxicology, Vanderbilt University Chemical Biology Seminar Series, Nashville, Tennessee.
115. Invited Speaker: **Nomura DK** (2016) Using Chemoproteomic Platforms for Toxicology and Drug Discovery GETA (Genetic and Environmental Toxicology Association) Symposium, Oakland, CA.
116. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. Gilead Medicinal Chemistry Seminar Series, Foster City, CA.
117. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. Gordon Conference on Bioorganic Chemistry, New Hampshire.
118. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. AACR National Meeting, New Orleans, Louisiana.
119. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. University of Pavia, Italy.
120. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Medical University of Graz, Graz, Austria.
121. Invited Speaker: **Nomura DK** (2016) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Keystone Science Lecture Speaker at National Institutes for Environmental Health Sciences, Research Triangle Park, North Carolina.
122. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Cleveland Clinic, Cleveland, Ohio.
123. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Purdue University, Department of Nutrition, Indiana.
124. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCLA, Los Angeles, California.
125. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. University of Wisconsin, Madison Department of Biochemistry, Madison, Wisconsin.
126. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCSF Cancer Center, San Francisco, CA
127. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCSF Endocrinology, San Francisco, CA
128. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. UCSD Bioengineering Department, La Jolla, CA
129. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Dana Farber Cancer Institute, Boston, Massachusetts.
130. Invited Keynote Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. Molecular and Cell Biology of Lipids Gordon Conference, Waterville Valley, New Hampshire.
131. Poster Presenter: **Nomura DK** (2015) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. High Throughput Chemistry and Chemical Biology Gordon Conference, New London, New Hampshire.
132. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Cancer using Chemoproteomic and Metabolomic Platforms. AACR Metabolism and Cancer meeting, Bellevue, Washington.
133. Invited Speaker: **Nomura DK** (2015) Mapping Metabolic Drivers of Disease using Chemoproteomic and Metabolomic Platforms. Lipid Maps Meeting 2015, La Jolla, CA.
134. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Metabolic Pathways in Disease Using Chemoproteomic and Metabolomic Platforms, Dana Farber/Harvard Medical School, Boston, MA.

135. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Metabolic Pathways in Disease Using Chemoproteomic and Metabolomic Platforms, Searle Meeting, Chicago, IL.
136. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Metabolic Pathways in Disease Using Chemoproteomic and Metabolomic Platforms, University of Chicago, Chicago, IL.
137. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Lipid Metabolism in Disease using Chemoproteomic and Metabolomic Platforms, RIKEN, Yokohama, Japan.
138. Invited Speaker: **Nomura DK** (2015) Mapping Dysregulated Lipid Metabolism in Disease using Chemoproteomic and Metabolomic Platforms, Phospholipase Meeting, Tokyo, Japan.
139. Seminar speaker: **Nomura DK** (2014) Chemoproteomic and Metabolomic Strategies for Drug Discovery and Toxicology, UC Berkeley, Nutritional Sciences and Toxicology Department
140. Poster/Talk: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Cancer Using Functional Proteomic and Metabolomic Platforms, Gordon Conference, Coenzymes, and Metabolic Pathways, Waterville Valley, NH.
141. Invited Speaker: **Nomura DK** (2014) Chemoproteomic and Metabolomic Strategies for Drug Discovery and Toxicology, Genentech, South San Francisco, CA Investigative Toxicology Division
142. Poster: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Cancer Using Functional Proteomic and Metabolomic Platforms, Searle Scholars Meeting, Chicago, IL.
143. Invited Speaker: **Nomura DK** (2014) Mapping Dysregulated Lipid Metabolism in Cancer using Chemoproteomic and Metabolomic Platforms, ASBMB meeting, San Diego, CA.
144. Invited Speaker: **Nomura DK** (2014) Mapping Dysregulated Lipid Metabolism in Cancer using Chemoproteomic and Metabolomic Platforms, Keystone Meeting on Tumor Metabolism, Whistler, Canada.
145. Invited Speaker: **Nomura DK** (2014) Validating Monoacylglycerol Lipase Inhibitors in Combatting Parkinson's Disease, Michael J Fox Foundation, New York, NY.
146. Invited Seminar Speaker: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, Karolinska Institute, Stockholm, Sweden.
147. Invited Seminar Speaker: **Nomura DK** (2014) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, University of Pavia, Pavia, Italy.
148. Invited Seminar Speaker: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, Novartis, Cambridge, MA.
149. Invited Seminar Speaker: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Disease using Chemoproteomic and Metabolomic Platforms, UC Merced, Merced, CA.
150. Invited Speaker: **Nomura DK** (2013) Endocannabinoid hydrolysis generates eicosanoids that promote inflammation. Bioactive Lipids in Cancer, Inflammation, and Related Diseases meeting, San Juan, Puerto Rico—received Eicosanoids Research Foundation Young Investigator Award.
151. Keynote Speaker: **Nomura DK** (2013) Chemoproteomic and Metabolomic Strategies for Drug Discovery and Toxicology. NorCal Society of Toxicology meeting, South San Francisco, CA.
152. Invited Speaker: **Nomura DK** (2013) Mapping dysregulated metabolic pathways in disease using functional proteomic and metabolomic platforms. Symposium on Frontier Sciences on New Drug Discovery, Tsinghua University, Beijing, China.
153. Invited Speaker: **Nomura DK** (2013) Mapping dysregulated metabolic pathways in disease using functional proteomic and metabolomic platforms. Transatlantic Frontiers of Chemistry (TFOC) meeting, American Chemical Society, Kloster Seon, Germany.
154. Invited Speaker: **Nomura DK** (2013) Endocannabinoid hydrolysis generates eicosanoids that promote inflammation. Gordon conference Molecular and Cellular Biology of Lipids, New Hampshire, NJ
155. Poster: **Nomura DK** (2013) Mapping dysregulated metabolic pathways in cancer. Gordon conference bioorganic chemistry, New Hampshire, NJ.
156. Poster: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Cancer Using Functional Proteomic and Metabolomic Platforms, Searle Scholars Meeting, Chicago, IL.
157. Invited Speaker: **Nomura DK** (2013) Mapping Dysregulated Metabolic Pathways in Disease using Functional Proteomic and Metabolomic Platforms. Seminar speaker at UC Berkeley, Department of Molecular and Cell Biology, Berkeley, CA
158. Invited Speaker: **Nomura DK** (2013) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Seminar speaker at University of Minnesota, Minneapolis, MN.
159. Invited Speaker: **Nomura DK** (2012) Mapping dysregulated metabolic pathways in disease using functional proteomic and metabolomic platforms. Seminar speaker at Agilent, Santa Clara, CA.

160. Invited Speaker: **Nomura DK** (2012) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Seminar speaker at Pfizer Neuroscience, Cambridge, MA.
161. Invited Speaker: **Nomura DK** (2012) Mapping Dysregulated Metabolic Pathways using Functional Chemoproteomic and Metabolomic Platforms. Seminar Speaker at Children's Hospital Oakland Research Institute, Oakland, CA.
162. Keynote Invited Speaker: **Nomura DK** (2012) Mapping dysregulated metabolic pathways in cancer using functional proteomic and metabolomic platforms. Austrian Proteomics Research Symposium, Graz, Austria.
163. Invited Speaker: **Nomura DK**. (2012) Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. *International Cannabinoid Research Society* meeting, Freiberg, Germany.
164. Poster: **Nomura DK** and Samad TA (2012) Metabolomic profiling for mapping anti-inflammatory pathways in neurodegenerative disease. *Genetics and Chemistry Cell Symposium*, Cambridge, Massachusetts.
165. Invited Speaker: **Nomura DK** (2012) Endocannabinoid hydrolysis generates brain eicosanoids that promote neuroinflammation. *SciCafe* hosted by Nature Biotechnology and Nature Medicine at the Gladstone Institute, San Francisco, CA
166. Poster: **Nomura DK** and Cravatt BF (2011) Monoacylglycerol Lipase Exerts Bidirectional Control over Endocannabinoid and Fatty Acid Pathways to Support Prostate Cancer. Cancer Chemical Biology meeting sponsored by Nature Chemical Biology, Cambridge, Massachusetts.
167. Invited Speaker: **Nomura DK** (2011) Mapping dysregulated metabolic pathways in cancer using activity-based proteomics. American Chemical Society meeting, Denver, Colorado.
168. Invited Speaker: **Nomura DK**, Cravatt BF (2011) Mapping dysregulated metabolic pathways in cancer. American Association for Cancer Research meeting, Orlando, Florida.
169. Invited Speaker: **Nomura DK**, Long JZ, Cravatt BF, Casida JE. (2010) Annotating the role of monoacylglycerol lipase in cancer and in the brain. American Chemical Society meeting, San Francisco, California.
170. Invited Speaker: **Nomura DK**. (2009) Chemical Approaches to Annotating Toxicological and Biological Systems. University of California Toxic Substances & Teaching Program Symposium, Berkeley, California.
171. Poster: **Nomura DK**, Blankman JL, Simon GM, Cravatt BF, Casida JE. (2008) Maximal activation of the endocannabinoid system by organophosphorus nerve agents. University of California Toxic Substances Research & Teaching Program Symposium, Riverside, California.
172. Poster: **Nomura DK**, Casida JE. (2007) Acetyl monoalkylglycerol ether deacetylase: an organophosphate detoxifying enzyme and modulator of tumor growth. IXth Meeting on Cholinesterases, Souzhou, China.
173. Oral Presentation: **Nomura DK**, Durkin KA, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2006) Toxicological and Structural Features of KIAA1363: A Novel Detoxifying Enzyme for Organophosphorus Nerve Poisons. American Chemical Society meeting, San Francisco, CA.
174. Poster: **Nomura DK**, Leung D, Chiang KP, Quistad GB, Cravatt BF, Casida JE. (2005) A Brain Detoxifying Enzyme for Organophosphorus Nerve Poisons. American Chemical Society meeting, Washington, D.C.

Students/Researchers Supervised (w/ former and current position)

Name	Position in the lab	Current Position
Aman Modi (2022-current)	Graduate Student	Scientist at Otsuka Pharma
Justin Hatcher (2022-current)	Undergraduate Researcher	
Taylor Nuttall (2022-current)	Graduate Student	
Lily Garelick (2022-current)	Undergraduate Researcher	
Yuki Terauchi (2022-current)	Visiting Scholar	
Melissa Lim (2022-current)	Graduate Student	
Hannah Rosen (2022-current)	Graduate Student	
Seong Ho (Johnny) Hong (2022-current)	Postdoctoral Fellow	
Hannah Grupe (2022-current)	Research Technician	
Nathan Hsu (2022-current)	Undergraduate Researcher	
Zoe Duong (2022-current)	Undergraduate Researcher	PhD program at Princeton University
Melissa Pighetti (2021-2022)		

Emily Heller (2021-current)	Oxford University Exchange Student	
Emily Ho (2021-current)	Undergraduate Researcher	
Halime Yilmaz (2021-current)	Undergraduate Researcher	
Amy Cho (2021-current)	Undergraduate Researcher	
Kaila Nishikawa (2021-current)	Undergraduate Researcher	
Anand Divakaran (2021-current)	Undergraduate Researcher	
Xavier Tao (2021-current)	Postdoctoral Fellow	
Belen E. Altamirano Poblano (2021-current)	Undergraduate Researcher	
Katelyn Randal (2021-2022)	Undergraduate Researcher	PhD program at Stanford University
Anoohya Panidapu (2021-current)	Undergraduate Researcher	
Vienna Thomas (2020-current)	Undergraduate Researcher	
Ethan Toriki (2020-current)	Graduate Student	
Margot Meyers (2020-current)	Graduate Student	
Abigail Estes (2020-2021)	Graduate Student	Lecturer at UC Berkeley
Elizabeth King (2020-current)	Graduate Student	
Nafsika Forte (2020-current)	Graduate Student	
James Papatzimas (2020-current)	Postdoctoral Fellow	
Matthew Cerda (2020-2021)	Postdoctoral Fellow	Scientist at Lonza
Charlotte Zammit (2020-current)	Postdoctoral Fellow	
Qian Shao (2020-current)	Postdoctoral Fellow	
Helen Bui (2020-2022)	Research Assistant	
Yangzhi (Robby) Wang (2020-current)	Professor	
Brian So (2019-2022)	Undergraduate Researcher	PhD program at Cornell University
Michelle Tang (2019-2022)	Undergraduate Researcher	PhD program at Stanford University
Jennifer Co (2019-2021)	Undergraduate Researcher	PhD program at Stanford University
Erika Zhang (2019-2022)	Undergraduate Researcher	PhD program at MIT
Lydia Zhang (2019-current)	Undergraduate Researcher	
Flor (Alicia) Gowans (2019-current)	Graduate Researcher	Scientist at Vicinitas Therapeutics
Nathaniel Henning (2019-2022)	Graduate Researcher	Student at Northwestern University
Deirdre Willgohs (2018-2018)	Graduate Researcher	Scientist at LifeMine Therapeutics
Benjamin Fontaine (2018-2021)	Research Intern	Scientist at Vicinitas Therapeutics
Lydia Boike (2018-2022)	Postdoctoral Fellow	PhD program at UCSF
Chad Altobelli (2018-2019)	Graduate Researcher	PhD program at Boston College
Angela Xiong (2018-2019)	Undergraduate Researcher	PhD program at Stanford University
Felix Majewski (2018-2020)	Undergraduate Researcher	Research Specialist at Scribe Therapeutics
Ross White (2018-2019)	Undergraduate Researcher	PhD program at Rice University
Sarah Buzsaki (2018-2020)	Undergraduate Researcher	Scientist at Hong Kong Jockey Club
May Fung (2018-2020)	Postdoctoral Fellow	MD/PhD student at Loyola Medicine
Sasha Demeulenaere (2018-2018)	Postdoctoral Fellow	
Kenneth Kim (2017-2021)	Undergraduate Researcher	
Samantha Tang (2017-2020)	Undergraduate Researcher	
Christine Thatcher (2017-2018)	Administrative and Lab Assistant	Scientist at Lawrence Livermore National Laboratory
Kyra Berger (2017-2018)	Undergraduate Researcher	
Yosuke Isobe (2018-2020)	Undergraduate Researcher	Deputy Team Leader at RIKEN
Clive Yik Sham Chung (2017-2020)	Postdoctoral Fellow	Assistant Professor at Hong Kong University
Katherine Near (2017-2019)	Postdoctoral Fellow	Scientist at Nurix
Alexander Cioffi (2017-2019)	Postdoctoral Fellow	Scientist at Frontier Medicines
Lisha Ou (2017-2019)	Postdoctoral Fellow	PhD program at Stanford University

Linda Waldherr (2017-2017) Raymond Ho (2017-2018) Sage Geher (2017-2017)	Undergraduate Researcher Visiting Grad Student Undergraduate Researcher Undergraduate Researcher	Postdoc, Medical Univ of Graz Research Assistant at University of Utah Assistant Professor at China Agricultural University
Mai Luo (2016-2020)	Postdoctoral Fellow	
Tamara Tomin (2016-2017) Alex Renn (2016-2017) Jordan Kleinman (2016-2019) Ashley Ives (2016-2017)	Visiting Grad Student Undergraduate Researcher Research Associate Undergraduate Researcher	PhD program at UCSF PhD program at Northwestern University
Sultana Mojadidi (2016-2016) Jessica Spradlin (2016-2020) Carl Ward (2016-2020) Allison Roberts (2015-2018) Amanda Wiggernhorn (2016-2019) Joseph Hendricks (2016-2017) Anna Flury (2016-2016) Haley Lehtola (2016-2018)	Undergraduate Researcher Graduate Researcher Graduate Researcher Graduate Researcher Research Associate Undergraduate Researcher Lab Assistant Undergraduate Researcher	Genentech Postdoctoral Fellow F99/K00 Postdoc at UCSF Scientist at Frontier Medicines PhD program at Stanford University PhD program at UC Berkeley
Yana Petri (2016-2019) Justin Wang (2016-2017) Ivan Atencio (2016-2017) Andrew Hong (2016-2016) Catherine Cascavita (2015-2016) Elizabeth Grossman (2014-2019) Michelle Luu (2015-2017) Deepika Raghavan (2015-2016) Peter Yan (2015-2017) Kimberly Anderson (2015-2018) Melanie Hubbuck (2015-2017) Megan Duckering (2015-2016)	Research Associate Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Lab Manager Graduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Graduate Researcher Graduate Researcher Undergraduate Researcher	Medical student at Western University of Health Sciences PhD student at MIT Process Engineer at EXP
Angela Yang (2015-2015)		Associate at Genentech Innovation Postdoc at Novartis Emergency Room Scribe at Vituity Medical Student at University of Iowa Medical Student at UCLA Scientist at Frontier Medicines PhD student at Washington University Senior Life Sciences Consultant at Guidehouse Research Assistant at Stanford University Associate Consultant with McKinsey and Company
Charles Berdan (2014-2019)	Undergraduate Researcher Graduate Researcher	
Wan-Min Ku (2014-2017) Derek Barbas (2014-2015) Leslie Bateman (2014-2016) Breanna Ford (2014-2019) Wallace Lowe (2014-2015) Tucker Huffman (2014-2017)	Undergraduate Researcher Undergraduate Researcher Postdoctoral Fellow Graduate Researcher Undergraduate Researcher Undergraduate Researcher	Senior Scientist at Neomorph Postdoc at BASF Graduate Student at TSRI in Ryan Shenvi's lab Account Manager at Quantcast
Olivia Dibenedetto (2014-2014) Jeffrey Coleman (2014-2014) Lara Bideyan (2014-2015) Esha Dalvie (2013-2016) Daniel Li (2013-2015) Jessica Counihan (2013-2018)	Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Graduate Researcher	PhD student at UCLA PhD program at Vanderbilt University Postbac at NIH Consultant for ClearView Healthcare Partners
Sharon Zhong (2013-2015) David Miyamoto (2013-2015) Karl Fisher (2013-2014) Lauryn Chan (2013-2014) Lucky Ding (2013-2016)	Undergraduate Researcher Undergraduate Researcher Associate Specialist Undergraduate Researcher	PhD program at Harvard University Director of Chemistry at Lygos Food Technologist at Beyond Meat Medical Student at UCSF

Nivedita Keshav (2013-2014) Ann Heslin (2013-2015) Chynna Tang (2013-2014)	Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher Undergraduate Researcher	Medical Student at UCLA Associate Product Manager at Veeva Graduate student in UC Berkeley Optometry Program Research Assistant at Genentech
Yoav Azaria (2012-2014) Devon Hunerdosse (2012-2015) Lindsay Roberts (2012-2017) Ramandeep Dhillon (2012-2015) Alice Shieh (2012-2013) Tara Narasimhalu (2012-2014) Rebecca Kohnz (2012-2016) Patrick Morris (2012-2014) Melinda Mulvihill (2012-2014) Alyssa Cozzo (2012-2013) Daniel Medina-Cleghorn (2011-2015) Jay Andrew Cosme Barcelon (2011-2012) McKenna Green (2012-2014)	Undergraduate Researcher Graduate Researcher Graduate Researcher Administrative and Lab Asst. Undergraduate Researcher Undergraduate Researcher Postdoctoral Fellow Postdoctoral Fellow Postdoctoral Fellow Undergraduate Researcher Graduate Researcher	Senior Research Biologist at 3M Senior Scientist, Nuredis Inc. Medical Doctor Undergraduate at Duke University Medical Resident at UCLA Senior Scientist at Merck Staff Scientist at NCI/NIH Senior Scientist at Genentech Researcher in Mina Bissell Lab, LBNL Scientist at Nurix
Daniel I Benjamin (2011-2015) Sharon M Louie (2011-2017) Anayo Ohiri (2011-2013) Jae Wong Chang (2009-2011) Anna M. Ward (2004-2008, 2010)	Undergraduate Researcher Undergraduate Researcher Graduate Researcher Graduate Researcher Undergraduate Researcher Graduate Researcher	Strategic Market Access & Intelligence Analyst at XCenda Resident Physician at Detroit Medical Center Postdoc at Stanford in Tom Rando Lab Scientist at CohBar Graduate Student at SF State Postdoctoral Fellow at U. Chicago Anesthesiology Resident at Harvard Medical School
Roger Issa (2004-2008)	Undergraduate Researcher Undergraduate Researcher	Principal Compliance Manager at Genentech